Chronic B-cell leukemias: Relation between morphological and immunological features

Ottolander, G. J. den; Schuit, H. R. E.; Waayer, Jacqueline L.M.; Huibregtsen, Loes; Hijmans, W.; Jansen, Jan

doi:10.1016/0090-1229(85)90082-0

Cited by 31 publications

(6 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…CD5 and this marker have been shown to be mutually exclusive [21]. Typically, malignant cells forming HCL do not express CD5 [ 18,30,31,32], although its expression has been reported occasionally [21,33]. Expression of CD5 is not a trait shared by immature B cell malignancies, such as pre-B acute lymphoblastic leukaemia, or by end-stage differentiated B cell malignancies [27,34], e.g.…”

Section: Leukaemiusmentioning

confidence: 99%

“…In contrast, PLL have been found to carry molecules recognized by MAb FMC-7 [29] or RFA-4 [27]. CD5 and this marker have been shown to be mutually exclusive [21]. Typically, malignant cells forming HCL do not express CD5 [ 18,30,31,32], although its expression has been reported occasionally [21,33].…”

Section: Leukaemiusmentioning

confidence: 99%

“…[3] from patients with chronic lymphocytic leukaemia (CLL) [24,26]. B cell markers are present on the leukaemic cells in all cases of PLL, but in some cases they do not express the CD5 marker [19,27], and only weakly to moderately in others [21,28]. In contrast, PLL have been found to carry molecules recognized by MAb FMC-7 [29] or RFA-4 [27].…”

Section: Leukaemiusmentioning

confidence: 99%

“…Thus, in most cases of CLL there is a proliferation of a B cell clone characterized by low amounts of surface immunoglobulins (Ig), the presence of MER and the expression of the CD5 antigen. Different subtypes of CLL have, however, been delineated, and CD5 is expressed on the leukaemic cells, not only from patients with true CLL, but also from patients with cleaved cell lymphocytic leukaemia ( 5 out of 12) and with lymphoplasmocytoid leukaemia (9 out of 21) [21]. The B cells of CLL with a particularly indolent character have been shown to be more frequently CD5+ than those B cells in patients with more aggressive CLL [25], but not correlation was T-lymphocyte-associated antigens were thus unexpectedly detected on chronic leukaemia B cells (Table 2) by complement-mediated lysis with rabbit antisera [2].…”

Section: Leukaemiusmentioning

confidence: 99%

See 3 more Smart Citations

Human CD5‐positive B Cells in lymphoid malignancy and connective tissue diseases

Youinou

Mackenzie

Lamour

et al. 1993

Eur J Clin Investigation

View full text Add to dashboard Cite

Abstract. The current literature on human CD5-positive B cells (CD5 + B cells) has been analysed, with a special emphasis on non organ-specific auto-immune diseases. Malignant cells of most of the chronic lymphoid leukaemias of the B cell lineage express the CD5 molecule. Antibodies of the IgM class produced by leukaemic B cells are multispecific auto-antibodies. The CD5+B cell subset may be expanded in non organ-specific autoimmune diseases, such as rheumatoid arthritis, primary Sjogren's syndrome, systemic lupus erythematosus. This holds true for various conditions, including organ-specific auto-immune diseases. Since auto-immune features are common in lymphoproliferative disorders, and the latter be a complication in non organ-specific auto-immune diseases, CD5 + B cells may represent an intermediatary between these auto-immune diseases and B cell lymphoproliferations. Studies on the regulation of CDS+B cell production and function are likely to shed light on the aetiology of, and pathogenetic mechanisms operating in the different disease states.

show abstract

Section: Leukaemiusmentioning

confidence: 99%

Section: Leukaemiusmentioning

confidence: 99%

Section: Leukaemiusmentioning

confidence: 99%

Section: Leukaemiusmentioning

confidence: 99%

See 2 more Smart Citations

Human CD5‐positive B Cells in lymphoid malignancy and connective tissue diseases

Youinou

Mackenzie

Lamour

et al. 1993

Eur J Clin Investigation

View full text Add to dashboard Cite

show abstract

“…The morphological and immunological characteristics of B-chronic lymphocytic leukaemia (B-CLL) have been described by several authors (1)(2)(3)(4). Nevertheless, a sharp distinction cannot be drawn between this disease and other lymphocytic proliferative disorders which can involve the blood (5). Transitional haematological patterns between B-CLL and prolymphocytic leukaemia (6)(7)(8) or hairy-cell leukaemia (9, 10) have been reported.…”

Section: Introductionmentioning

confidence: 98%

B‐cell chronic lymphocytic leukaemia stage 0. An immunophenotypic study of 66 cases and comparison with B small cell lymphomas*

Stramignoni¹,

Valente²,

Geuna³

et al. 1994

European J of Haematology

View full text Add to dashboard Cite

The cells of 66 B‐CLL stage 0 patients were analyzed using a large panel of monoclonal antibodies in order to better define the immunophenotype of B‐CLL. The data were compared with the immunophenotypes of lymph node cells from 51 patients with diffuse B small cell lymphoma or leukaemia with lymph node enlargement. The most frequent immunophenotype of B‐CLL stage 0 was SIgM(D)+ EmR+ CD5+ CD9+ CD21+ CD23+ CD35– CD38–. Among the lymphomas, EmR‐positive and EmR‐negative cases were identified. The vast majority of the EmR‐positive cases usually showed the leukaemic pattern, immunophenotype and lymph node histology of B‐CLL. The EmR‐negative cases usually had immunophenotypes quite different from those of B‐CLL and the histology of indented cell lymphoma (centrocytic or intermediate) or features of lymphoplasmacytoid/cytic lymphoma. More than 20% of EmR‐positive cells proved to be the most important marker to distinguish B‐CLL from other lymphocytic lymphomas. Indeed this was a sign of better prognosis. Lymphoplasmacytoid/cytic lymphomas were EmR‐positive with the immunophenotype of B‐CLL or EmR‐negative with a definitely different immunological profile. This suggests two morphologically similar but biologically different subgroups of these diseases.

show abstract

Intracellular immunoglobulin G ‘Pseudocrystals’ in a patient with chronic B-cell leukemia

Ottolander

Brederoo

Schuurman

et al. 1986

Cancer

Self Cite

View full text Add to dashboard Cite

A patient with chronic B-cell leukemia in whom the malignant lymphocytes showed intracellular inclusions of immunoglobulin (Ig) G kappa molecules is described. Electron microscopy revealed filamentous material in the nuclear envelopes and in the cisternae of the rough endoplasmic reticulum. These in vivo surface Ig-negative, nonexcreting cells could be stimulated in vitro to excrete immunoglobulin-free light chain molecules into the supernatant, which were not found in the cytoplasm after stimulation.

show abstract

Chronic B-cell leukemias: Relation between morphological and immunological features

Cited by 31 publications

References 28 publications

Human CD5‐positive B Cells in lymphoid malignancy and connective tissue diseases

Human CD5‐positive B Cells in lymphoid malignancy and connective tissue diseases

B‐cell chronic lymphocytic leukaemia stage 0. An immunophenotypic study of 66 cases and comparison with B small cell lymphomas*

Intracellular immunoglobulin G ‘Pseudocrystals’ in a patient with chronic B-cell leukemia

Contact Info

Product

Resources

About